Startup profile · funding coverage

Ona Therapeutics

Barcelona biopharma Ona Therapeutics closed an oversubscribed $86.6M Series B in June 2026 to advance first-in-class antibody-drug conjugates for resistant cancers.

Stage

series b

Status

private

Coverage

full

Why Ona Therapeutics is interesting

Treatment-resistant cancers evade existing therapies. Ona develops first-in-class antibody-drug conjugates (ADCs) — targeted payloads designed to kill cancer cells that current drugs can't reach. - ADCs are one of oncology's hottest modalities. - Treatment resistance is a major unmet need. - The reopening exit market improves European biotech funding appetite. Barcelona biopharma Ona Therapeutics closed an oversubscribed $86.6M Series B in June 2026 to advance first-in-class antibody-drug conjugates for resistant cancers.

Key facts

Disclosed financing: $86.6M (Series B)
Covered in 1 Venture Capital Tracker article(s)

Industries

Healthtech Biotech & Life Sciences

Industry hub pages are rolling out from our fund-derived baseline taxonomy.